New Key Statistics Module, Z-Score and F-Score
NAS:NAMS Key Ratios
| Market Cap $ M | 1,436.64 |
| Enterprise Value $ M | 1,015.50 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 3.71 |
| Price/Sales | 396.26 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 3.00 |
| EPS (TTM) $ | -2.62 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -9.57 |
| EV-to-EBITDA | -9.58 |
| PEG | -- |
| Shares Outstanding M | 90.02 |
| Net Margin (%) | -3,607.99 |
| Operating Margin % | -2,880.08 |
| Pre-tax Margin (%) | -3,607.99 |
| Quick Ratio | 9.83 |
| Current Ratio | 9.83 |
| ROA % (ttm) | -29.60 |
| ROE % (ttm) | -34.34 |
| ROIC % (ttm) | -205.57 |
| Dividend Yield % | -- |
| Altman Z-Score | 12.99 |
NAMS Number of Guru Trades
NAMS Volume of Guru Trades
Gurus Latest Trades with NAS:NAMS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:NAMS is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NewAmsterdam Pharma Co NV Insider Transactions
No Available Data
News about NAS:NAMS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers